PCR for Aspergillus Fumigatus in Blood and Bronchoalveolar Lavage Fluid for Monitoring Cases of Invasive Aspergillosis: What is Its Prognostic Value

Aspergillus fumigatus PCR is currently used in conjunction with serum galactomannan to support the diagnosis of invasive aspergillosis or for monitoring at-risk patients not receiving antifungal prophylaxis. A positive result and a high titer are thought to be associated with the advanced stage of the disease and the fungal load. However, there is limited data on this subject, and no study has primarily focused on the variation of PCR levels during treatment and its potential correlation with treatment efficacy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Invasive Pulmonary Aspergillosis Aspergillosis Bacterial Infections and Mycoses Infections Invasive Fungal Infections Lung Diseases Lung Diseases, Fungal Mycoses Pulmonary Aspergillosis Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Alia BARTHEL, MD

PRINCIPAL_INVESTIGATOR

Baptiste Hoellinger, MD

CONTACT

[email protected]

33 3 69 55 05 45

Baptiste Hoellinger, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients aged 18 years or older
Positive Aspergillus fumigatus PCR on serum or bronchoalveolar lavage fluid at diagnosis, performed at the Strasbourg University Hospital between January 1, 2017, and December 31, 2024.

Exclusion criteria

No subsequent Aspergillus fumigatus PCR (>24h)
No diagnosis of probable or proven invasive aspergillosis (EORTC/MSGERC 2020 criteria)
Effective antifungal treatment against Aspergillus initiated before the first PCR
Death <72h after starting antifungal treatment

Treatment and study plan

Primary outcomes

Death rate at day 30 in patients with a positive follow-up PCR (blood or bronchoalveolar lavage)

Time frame: Day 30 post-antifungal treatment

Death rate at day 30 in patients with a positive follow-up PCR (blood or bronchoalveolar lavage) after the start of treatment

Study contacts

Contact information is provided by the study sponsor or research team.

baptiste Hoellinger, MD

CONTACT

[email protected]

33 3 69 55 05 45

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: ASP

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Jan 2, 2026
Registry last updated: Jan 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting